COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Fundamental Risk Analysis including financial ratios, debt levels, liquidity, and sustainability metrics. Compare against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Fundamental Risk Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.

Debt-to-Equity Ratio

0.34

Increased from previous period

D/E ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.07. Howard Marks would check for debt covenant compliance and refinancing risks.

Net Debt-to-EBITDA

0.05

Increased from previous period

Exceptionally low net debt at less than half the Medical - Pharmaceuticals median of 2.57. Joel Greenblatt would praise this conservative approach, but verify Operating Margins versus peers.

Interest Coverage Ratio

180.70

Decreased from previous period

Coverage of 180.70 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.

Current Ratio

0.71

Increased from previous period

Current ratio below 50% of Medical - Pharmaceuticals median of 3.46. Michael Burry would check for immediate refinancing needs.

Intangibles-to-Total-Assets Ratio

0.22%

Decreased from previous period

Intangibles less than half the Medical - Pharmaceuticals median of 3.14%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.

Select Chart Metric:

3349.T Fundamental Risk Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Debt-to-Equity Ratio

0.34

Increased from previous period

D/E ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.07. Howard Marks would check for debt covenant compliance and refinancing risks.

Net Debt-to-EBITDA

0.05

Increased from previous period

Exceptionally low net debt at less than half the Medical - Pharmaceuticals median of 2.57. Joel Greenblatt would praise this conservative approach, but verify Operating Margins versus peers.

Interest Coverage Ratio

180.70

Decreased from previous period

Coverage of 180.70 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.

Current Ratio

0.71

Increased from previous period

Current ratio below 50% of Medical - Pharmaceuticals median of 3.46. Michael Burry would check for immediate refinancing needs.

Intangibles-to-Total-Assets Ratio

0.22%

Decreased from previous period

Intangibles less than half the Medical - Pharmaceuticals median of 3.14%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.

Select Chart Metric: